– Annual shareholder meeting planned for May 19, 2021 – Company to host conference call today at 4:30 pm ET BOSTON , May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the first quarter ended March
Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event BOSTON , May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, will present and
Annual shareholder meeting to be held on May 19, 2021 BOSTON , April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder
Presentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies BOSTON , April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, was the inaugural
BOSTON and HOUSTON and TAIPEI, Taiwan , April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being
Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers BOSTON and HOUSTON , April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper ; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance
Company to Hold R&D Day on Thursday, March 11, 2021 BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on
BOSTON , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of